Effect and Complications of Everolimus Use for Giant Cardiac Rhabdomyomas with Neonatal Tuberous Sclerosis

Yuka Shibata, MD1  Hidehiko Maruyama, MD, PhD1  Taiyu Hayashi, MD2  Hiroshi Ono, MD2  Yuka Wada, MD, PhD1  Hideshi Fujinaga, MD, PhD1  Shuhei Fujino, MD1  Junko Nagasawa, MD1  Shoichiro Amari, MD1  Keiko Tsukamoto, MD1  Yushi Ito, MD1

1 Division of Neonatology, Center for Maternal-Fetal, Neonatal and Reproductive Medicine, Setagaya, Tokyo, Japan  2 Division of Cardiology, National Center for Child Health and Development, Setagaya, Tokyo, Japan

Am J Perinatol 2019;9:e213–e217.

Address for correspondence: Hidehiko Maruyama, MD, PhD, Division of Neonatology, Center for Maternal-Fetal, Neonatal and Reproductive Medicine, National Center for Child Health and Development, 2-10-1 Okura, Setagaya, Tokyo, Japan (e-mail: maruyama-h@ncchd.go.jp).

Abstract

Most cardiac rhabdomyomas with tuberous sclerosis (TS) are asymptomatic and spontaneously regress. However, some cases require surgical intervention due to arrhythmia and severe obstruction of cardiac inflow or outflow. We report herein a neonatal case of giant cardiac rhabdomyomas with TS and insufficient pulmonary blood flow from the right ventricle. Lipoprostaglandin E1 was necessary to maintain patency of the ductus arteriosus. We used everolimus, a mammalian target of rapamycin inhibitor, to diminish the cardiac rhabdomyomas. After treatment, the rhabdomyomas shrank rapidly, but the serum concentration of everolimus increased sharply (maximum serum trough level: 76.1 ng/mL) and induced complications including pulmonary hemorrhage, liver dysfunction, and acne. After the everolimus level decreased, the complications resolved. Everolimus may be a viable treatment option for rhabdomyomas, but its concentration requires close monitoring to circumvent complications associated with its use.

Tuberous sclerosis (TS) is caused by loss-of-function mutations of the TSC1 or TSC2 gene.1 TSC1 and TSC2, respectively, encode hamartin and tuberin, which combine to suppress the mammalian target of rapamycin (mTOR) signaling pathway.2,3 The mTOR signaling pathway regulates cell proliferation and vascularization.4 In patients with TS, the mTOR signaling pathway is abnormally activated due to diminished hamartin or tuberin function, leading to hamartomatous cell growth and other symptoms.2,3 Cardiac rhabdomyoma is one of the features of TS in the neonatal and early infantile periods. In half of rhabdomyoma cases, the rhabdomyomas spontaneously regress in childhood.5

Everolimus is an mTOR inhibitor. Its effectiveness against subependymal giant cell astrocytomas,3,6 renal angiomyolipomas,7 and epilepsy8 in patients with TS has been documented.

There are some reports of cardiac rhabdomyoma treatment using everolimus,9–17 but none describes the serious complications associated with its use. We report herein a neonate with TS and giant cardiac rhabdomyomas occupying the right ventricular cavity, impeding ventricular function, and decreasing pulmonary blood flow. Lipoprostaglandin E1 (lipo-PGE1) was required to maintain patency of the ductus arteriosus. Everolimus administration successfully reduced the tumor size although the serum concentration of everolimus increased sharply (maximum serum trough level: 76.1 ng/mL) and induced complications including pulmonary hemorrhage, liver dysfunction, and acne. After the everolimus level decreased, the complications resolved. Everolimus may be a viable treatment option for rhabdomyomas, but its concentration requires close monitoring to circumvent complications associated with its use.

Keywords

► complication
► everolimus
► rhabdomyoma
► tuberous sclerosis

Case Report

A 43-year-old woman was referred for fetal echocardiography at 21 gestational weeks due to multiple intracardiac
tumors. Although the fetus had cardiac enlargement with a cardiac thoracic area ratio of 67% at 35 gestational weeks, the fetus developed neither arrhythmia nor hydrops.

A male infant was born at 38 weeks' gestation by scheduled cesarean section due to a previous cesarean section. The birth weight was 2,029 g, the heart rate was 138 beats per minute, the respiratory rate was 20 breaths per minute, the blood pressure was 60/37 mm Hg, and oxygen saturation was 90% without any respiratory support at neonatal intensive care unit admission. A systolic heart murmur (grade 4/6) and peripheral coldness were found. There was no skin lesion, and the blood test showed no abnormalities.

The largest intracardiac tumor, 35 mm × 21 mm in size, occupied the right ventricular cavity (Fig. 1a), resulting in decreased right ventricular output. Echocardiography showed scant antegrade blood flow via the pulmonary valve and significant pulmonary regurgitation caused by backward blood flow from the ductus arteriosus. The right atrium was dilated, and a right-to-left shunt through the foramen ovale was detected. Stenosis of the left ventricular outflow tract due to the tumor was observed, and the flow velocity of the ascending aorta increased (1.5 m/s), but the systemic blood pressure remained normal. Since the pulmonary blood flow was dependent on the ductus arteriosus, we started lipo-PGE1 (5 ng/kg/min) soon after birth to maintain patency of the ductus arteriosus, conotruncal anomaly repair, and improved after 2 weeks. Hyperlipidemia, hyperglycemia, and stomatitis were not observed.

A magnetic resonance imaging of the brain showed cerebral white matter radial migration lines, a cortical tuber, and a subependymal hamartoma. Multiple retinal nodular hamartomas were also observed. TS was diagnosed based on these three major findings (brain, retina, and heart).¹

Volume reduction of the cardiac rhabdomyomas was crucial to maintain pulmonary blood flow. We decided to use everolimus to reduce the cardiac rhabdomyomas rapidly. We started once daily oral everolimus administration on day 4. The initial dosage of 0.4 mg/d (2.8 mg/m²/d, 0.2 mg/kg/d) was decided based on previous reports.³,¹⁸ The target trough level was set at 5 to 15 ng/mL.⁶ Echocardiography at day 7 demonstrated a decrease in the tumor size in the right ventricle and an increase in the antegrade blood flow via the pulmonary valve. We terminated lipo-PGE1.

We experienced a serious complication at day 6, 3 days after the initiation of everolimus administration, when the patient’s respiratory condition worsened and mechanical ventilation was started. Continuous bloody tracheal aspiration indicated a pulmonary hemorrhage, and the laboratory data revealed severe coagulopathy with a prothrombin time–international normalized ratio (PT-INR) of 2.4 and fibrinogen value of 52 mg/dL, as well as elevated liver enzymes. We decided to stop everolimus on day 7 after the fourth administration. After a single infusion of fresh-frozen plasma, the coagulopathy improved (PT-INR 1.6 and fibrinogen 158 mg/dL) at day 9. Acne, which appeared on the bilateral cheeks at day 8, was treated with topical quinolone medication and improved after 2 weeks. Hyperlipidemia, hyperglycemia, and stomatitis were not observed.

Echocardiography at day 16 showed closure of the ductus arteriosus, confirming that biventricular circulation was achieved. The patient was weaned from mechanical ventilation on the same day.

With general improvement in the patient’s condition, we tried to restart everolimus in the hope of further reducing the tumor size. At day 10, everolimus was administered at a lower dose of 0.1 mg/d. However, we discontinued everolimus again after we obtained the serum drug concentration measurement for day 7 showing a trough level of 76.1 ng/mL, which significantly exceeded the target level. At day 25, everolimus was administered at a dose of 0.025 mg/d, which resulted in a re-elevation of the liver enzymes. After everolimus was terminated altogether, the liver enzyme levels normalized again. Changes in the serum everolimus concentration and liver enzymes are shown in Fig. 2.

Echocardiography at days 20 (Fig. 1b) and 42 (Fig. 1c) showed regression of the giant tumor in the right ventricle. The patient was discharged at day 54.

Discussion

Everolimus was effective as a treatment of the giant cardiac rhabdomyomas with TS in our case; the drug reduced the tumor size rapidly, increased pulmonary blood flow, and
rendered surgical intervention unnecessary. Several reports have demonstrated the effectiveness of this drug (Table 1).9-17 Cardiac rhabdomyomas with TS usually spontaneously regress in childhood.3 Therapeutic intervention is not needed unless arrhythmia or severe intracardiac obstruction occurs.19 In cases of refractory arrhythmia or severe obstruction of blood flow, surgery for tumor resection or single ventricular hemodynamics is necessary during the neonatal period.20 Given the effectiveness of everolimus in rapidly reducing the size of rhabdomyomas, the drug may be a viable treatment option for giant cardiac rhabdomyomas in patients with TS.

The appropriate dosage of everolimus has not been determined. Previous studies have set the everolimus target trough level at 5 to 15 ng/mL.9,10,12-17 The package insert recommends monitoring the serum drug concentration from 2 weeks after commencing administration or changing the dosage. In our case, everolimus was administered at a dose of 0.2 mg/kg once daily starting at day 4. The serum everolimus concentration, measured immediately before the administration of the 4th dose at day 7, was 76.1 ng/mL, which was much higher than the target trough level. Our measurement of the serum drug concentration, which we made much earlier than recommended by the package insert, indicated that the initial dose should have been lower. Although the half-life of the drug is reportedly 25 to 43 hours, the estimated half-life in our case was 84 to 128 hours, far exceeding the reported values. Our case underscores the fact that meticulous monitoring of the serum drug concentration is essential.

Our patient developed pulmonary hemorrhage coinciding with the elevation of the serum everolimus concentration. Everolimus reportedly damages not only tumor vessels but also normal blood vessels22 and can lead to pulmonary hemorrhage.23 A recent in vivo study suggested that mTOR inhibitors may interact with the STAT1 gene, causing amplification of cellular apoptosis and augmenting lung injury.24 Coagulopathy, which developed in our patient, is another possible complications. In the present case, in addition to increased pulmonary blood flow due to lipo-PGE1, tumor shrinkage caused by everolimus increased the pulmonary blood flow. All these factors contributed to the pulmonary hemorrhage.

Everolimus can adversely affect liver function and lead to decreased metabolism of the drug. In our patient, an elevation of aspartate transaminase and alanine transaminase was evident at day 7 when the serum everolimus concentration peaked, and acne was also observed. As summarized in Table 1, complications reported in neonates include mouth ulcers, hyperlipidemia, etc. Liver dysfunction and acne were listed among the possible complications in the package insert in 2018, in which the incidence rates of liver dysfunction and acne were 1 to 10%. Half the Japanese population lack the activity of CYP3A5, the enzyme involved in everolimus metabolism.21,25 Although we did not assess enzyme activity in our patient, the extremely high concentration of everolimus and the prolongation of its half-life might be related to the lack of CYP3A5 activity.

The toxic and therapeutic levels of the serum everolimus concentration also require clarification. Complications, such as mouth ulcer and hyperlipidemia, have been documented in patients with concentrations of everolimus below the target trough level of 5 to 15 ng/mL.9,11,15 In contrast, there were no complications in a case reported by Shigemitsu et al13 despite a maximum trough level of 21 ng/mL.

Follow-up after the cessation of everolimus treatment is also important. Some studies reported tumor regrowth after stopping everolimus administration.11,12 It is also necessary to follow the long-term growth and development of pediatric patients who have received everolimus. There are as yet no reports on the long-term prognosis of neonates or young children who have received this treatment.26

In conclusion, everolimus may be a viable treatment option for giant cardiac rhabdomyomas in patients with TS. When administering the drug to neonates, the patient should be closely observed for possible side effects, and the serum drug level should be routinely monitored.
| Case | GA (wk) | BW (g) | Maximum tumor diameter (mm) | Start of everolimus treatment (d) | Drug dosage | Calculated dosage (mg/kg/wk) | Everolimus trough level (ng/mL) | Complications | Outcomes | Reference |
|------|---------|--------|-----------------------------|----------------------------------|-------------|-----------------------------|-------------------------------|----------------|----------|-----------|
| 1    | 38      | 3,350  | 8                           | 1                                | 0.1 mg/d    | 0.21                        | 10.2                          | Mouth ulcer, suspected infection | 50% reduction in size of largest RHM, with some RHM disappearing after 36 d | Aw et al (2017)⁹ |
| 2    | Term    | 3,550  | 24                          | 2                                | 0.5 mg/d, twice a week | 0.28                | 7.8                           | NA                         | Significant reduction of RHM over 2 mo | Doğan et al (2015)¹⁰ |
| 3    | 38      | 3,500  | 20                          | 7                                | 0.5 mg/d, twice a week | 0.29                | 2.6                           | Hyperlipidemia              | Significant reduction of RHM over 4 wk, but treatment resumed as RHM increased again 10 d after discontinuation of treatment. After 7 mo, treatment was tapered and discontinued | Bornaun et al (2016)¹¹ |
| 4    | 36      | 1,670  | 27.2                        | 4                                | 0.1 mg/d    | 0.42                        | 11                            | None                      | Significant reduction of RHM over 20 d. RHM increased again after stopping everolimus but was asymptomatic | Goyer et al (2015)¹² |
| 5    | 37      | 2,930  | 36                          | 19                               | 1 mg/m²/d   | 0.48                        | 21                            | None                      | Rapid regression within a few weeks | Shigemitsu et al (2016)¹³ |
| 6    | Term    | 3,400  | 25                          | 0                                | 1 mg/d, twice a week | 0.59                | 83.5                          | Hyperlipidemia             | Remarkable reduction of RHM over 2.5 mo. Two out of six RHM disappeared | Demir et al (2012)¹⁴ |
| 7    | 30      | 980    | 16                          | 20                               | 0.1 mg/d    | 0.71                        | 13.7                          | Fever, respiratory deterioration | BT shunt operation was done at 88 d of life. Afterward, two-ventricle repair was done with no need for RHM resection | Mohamed et al (2014)¹⁵ |
| 8    | 35      | 2,000  | 40                          | 1 wk                             | 0.25 mg/d   | 0.88                        | 16                            | Mucositis, hyperlipidemia | 80% reduction in size of major RHM over 10 wk | Colaneri et al (2016)¹⁶ |
| 9    | Term    | 2,955  | 37                          | 2                                | 0.4–0.45 mg/d | 1.07                | 108                           | Hyperlipidemia, lymphopenia | Giant LV RHM continued to shrink (21 × 37 × 21 mm–10 × 28 × 13 mm) over 3 wk | Wagner et al (2015)¹⁷ |
| 10   | 38      | 2,029  | 35                          | 4                                | 0.4 mg/d    | 1.38                        | 76.1                          | Pulmonary hemorrhage, acne, liver dysfunction | After 4 everolimus doses, tumors shrank. Actual right ventricle volume and right ventricle output increased, and biventricular circulation was established | Our case |

Abbreviations: BT, Blalock–Taussig; BW, birth weight; GA, gestational age; LV, left ventricle; NA, not applicable; RHM, rhabdomyoma.

Note: Everolimus dosage was assumed to be 0.45 mg/d in case 9.
Ethical Approval
All the procedures involving human participants were performed in accordance with the ethical standards of the institution and with the 1964 Helsinki declaration and its later amendments. The approval of the ethics review committee and parental consent to use everolimus were obtained. Parental written informed consent was obtained for this report.

Funding
No financial assistance was received to support this study.

Conflict of Interest
All the authors declare that they have no conflict of interest.

Acknowledgment
We thank Mr. James R. Valera for his assistance with editing this article.

References
1. Northrup H, Krueger DA; International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 2013;49(04):243–254
2. Chan JA, Zhang H, Roberts PS, et al. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. J Neuropathol Exp Neurol 2004;63(12):1236–1242
3. Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010;363(19):1801–1811
4. Potter CJ, Huang H, Xu T. Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell 2001;105(03):357–368
5. Smythe JF, Dyck JD, Smallhorn JF, Freedom RM. Natural history of cardiac rhabdomyoma in infancy and childhood. Am J Cardiol 1990;66(17):1247–1249
6. Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST–1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013;381(9861):125–132
7. Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST–2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013;381(9869):817–824
8. Krueger DA, Wilfong AA, Holland-Bouley K, et al. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol 2013;74(05):679–687
9. Aw F, Goyer I, Raboisson MJ, Boutin C, Major P, Dahdah N. Accelerated cardiac rhabdomyoma regression with everolimus in infants with tuberous sclerosis complex. Pediatr Cardiol 2017;38(02):394–400
10. Doğan V, Yeşil Ş, Kayali Ş, et al. Regression of symptomatic multiple cardiac rhabdomyomas associated with tuberous sclerosis complex in a newborn receiving everolimus. J Trop Pediatr 2015;61(01):74–77
11. Bornaun H, Öztarhan K, Ererener-Ercan T, et al. Regression of cardiac rhabdomyomas in a neonate after everolimus treatment. Case Rep Pediatr 2016;2016:8712962
12. Goyer I, Dahdah N, Major P. Use of mTOR inhibitor everolimus in three neonates for treatment of tumors associated with tuberous sclerosis complex. Pediatr Neurol 2015;52(04):450–453
13. Shigemitsu Y, Baba K, Kondo M, et al. Regression of massive cardiac rhabdomyoma causing circulatory collapse with everolimus therapy. Pediatr Cardiol Cardiac Surg 2016;32:439–444
14. Demir HA, Ekici F, Yazal Erdem A, Emir S, Tunç B. Everolimus: a challenging drug in the treatment of multifocal inoperable cardiac rhabdomyoma. Pediatrics 2012;130(01):e243–e247
15. Mohamed I, Ethier G, Goyer I, Major P, Dahdah N. Oral everolimus treatment in a preterm infant with multifocal inoperable cardiac rhabdomyoma associated with tuberous sclerosis complex and a structural heart defect. BMJ Case Rep 2014;2014 pii: bcr2014205138
16. Colaneri M, Quarti A, Pozzi M. Everolimus-induced near-resolution of giant cardiac rhabdomyomas and large renal angiomyolipoma in a newborn with tuberous sclerosis complex. Cardiol Young 2016;26(05):1025–1028
17. Wagner R, Riede FT, Seki H, et al. Oral everolimus for treatment of a giant left ventricular rhabdomyoma in a neonate-rapid tumor regression documented by real time 3D echocardiography. Echo-cardiology 2015;32(12):1876–1879
18. Fujino M, Ehara E, Kuki I, et al. Rapid regression of cardiac rhabdomyoma after everolimus administration in an infant with tuberous sclerosis. Pediatr Cardiol Cardiac Surg 2016;32:251–256
19. Stiller B, Hetzer R, Meyer R, et al. Primary cardiac tumours: when is surgery necessary? Eur J Cardiothorac Surg 2001;20(05):1002–1006
20. Bielefeld KJ, Moller JH. Cardiac tumors in infants and children: study of 120 operated patients. Pediatr Cardiol 2013;34(01):125–128
21. Masuda S. Individualized dosage of everolimus in organ transplant patients by evidence based medicine. Organ Biology 2015;22:105–110
22. Kubota Y. Tumor angiogenesis and anti-angiogenic therapy. Keio J Med 2012;61(02):47–56
23. Vandewiele B, Vandecasteele SJ, Vanvalleghem L, De Vriese AS. Diffuse alveolar hemorrhage induced by everolimus. Chest 2010;137(02):456–459
24. Fiilhaber JA, Carroll SF, Dydensborg AB, et al. Inhibition of mammalian target of rapamycin augments lipopolysaccharide-induced lung injury and apoptosis. J Immunol 2012;188(09):4535–4542
25. Uesugi M, Kikuchi M, Shinke H, et al. Impact of cytochrome P450 3A5 polymorphism in graft livers on the frequency of acute cellular rejection in living-donor liver transplantation. Pharmacogenet Genomics 2014;24(07):356–366
26. Kotulska K, Chmielewski D, Borkowska J, et al. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Eur J Paediatr Neurol 2013;17(05):479–485